Psychedelics Briefs: Field Trip, Cybin Receive Conditional Stock Listing Approvals; Mydecine Applies for Patent

Field Trip Health, a Toronto-based psychedelic therapies company, has received conditional approval to list its issued and outstanding shares on the NASDAQ Global Select Market. Final approval is subject to Field Trip fulfilling remaining conditions set forth by NASDAQ.

The company will continue to trade its shares in Canada on the Toronto Stock Exchange, and until its NASDAQ listing receives final approval, on the OTCQX in the United States.

Field Trip CEO Joseph del Moral said in a news release that the NASDAQ listing will improve liquidity at “a critical time for us to increase our visibility in the marketplace.”

Cybin receives conditional listing approval from NYSE American

Cybin, a psychedelic therapeutics biotech firm, announced last week that it has received conditional listing approval from the NYSE American stock exchange, becoming the first psychedelics company to do so. The organization plans to maintain its listing on the NEO Exchange as well.

Cybin CEO Doug Drysdale called the conditional approval from NYSE American “an important milestone” for the company.

“We expect expanded access to investors to further fuel our mission to develop revolutionary psychedelic therapeutics for patients suffering from mental health conditions,” Drysdale said in a news release.

Mydecine files patent for MDMA-like compounds

Mydecine, a Denver-based biopharma and life sciences company, has filed a new patent for MDMA-like compounds, a potential treatment option for PTSD that would expand the company’s portfolio of novel compounds. With its newly filed patent on entactogenic compounds, Mydecine is aiming to further develop treatments that reduce harm and improve safety vs. the use of traditional MDMA.

“This filing is part of our continued efforts to grow our robust IP portfolio as we consistently file for new patents that offer high potential to expand psychedelics for medical use,” Mydecine chief scientific officer Rob Roscow said in a release.